Clene stock surges 20% after FDA meeting on ALS drug approval
Investing.com Gold reports: Clene stock surges 20% after FDA meeting on ALS drug approval. Full body text was unavailable at ingest time, so this brief is based on headline context.
Investing.com Gold reports: Clene stock surges 20% after FDA meeting on ALS drug approval. Full body text was unavailable at ingest time, so this brief is based on headline context.